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http://www.biomedcentral.com/1471-2407/13/158RESEARCH ARTICLE Open AccessAdvance lung cancer inflammation index (ALI) at
diagnosis is a prognostic marker in patients with
metastatic non-small cell lung cancer (NSCLC):
a retrospective review
Syed H Jafri1,2*, Runhua Shi1,2 and Glenn Mills1,2Abstract
Background: Systemic inflammation has been linked with cancer development, cancer cachexia and poor
outcome. Advanced lung cancer inflammation index (ALI) was developed to assess degree of systemic
inflammation at the time of diagnosis in metastatic non-small cell lung (NSCLC) cancer patients.
Methods: In a single institution retrospective review 173 patients with metastatic NSCLC diagnosed between
Jan 1 2000 and June 30 2011 were included. ALI was calculated as (BMI x Alb / NLR) where BMI = body mass index,
Alb = serum albumin, NLR (neutrophil lymphocyte ratio, a marker of systemic inflammation). Patients were divided
into low inflammation (ALI ≥ 18) and high inflammation (ALI < 18) groups. Kaplan-Meier method was used to
estimate progression free survival and overall survival. Log-rank test were used to compare the survivals among
various factors. Multivariate Cox regression was used to perform survival analysis in order to estimate the hazards
ratio for various factors.
Results: Among 173 patients median age was 57 years, 67% were male, 52% had adenocarcinoma. Patients with
an ALI score of < 18 suggesting high systemic inflammation were significantly more likely to have more than 2 sites
of metastatic disease, have poor performance status and less likely to receive any chemotherapy. Their median
progression free survival and overall survival was 2.4 months and 3.4 months as opposed to 5.1 months and
8.3 months in patients with ALI >18 (P < 0.001). On multi-variate analysis ALI score of <18 (1.42, 95% CI 1.003-2.01)
remained significantly associated with worse outcome.
Conclusion: ALI (<18) at diagnosis is an independent marker of poor outcome in patients with advanced NSCLC.
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Lung cancer is one of the most commonly diagnosed
cancers in the United States. It is estimated that 226,160
new cases of lung cancer will be diagnosed and 160,340
will die from it in year 2012 alone [1]. 85% of lung can-
cer cases are classified as non-small cell lung cancer
(NSCLC) and the rest (15%) are classified as small cell
lung cancer(SCLC) [2]. NSCLC is further classified based
on histology, 29% of diagnosed cases have squamous cell* Correspondence: sjafri@lsuhsc.edu
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reproduction in any medium, provided the orcancer (SCC) and approximately 32% have adenocarcin-
oma and the rest have other sub-types [3]. More than half
of the patients (56%) with lung cancer at the time of diag-
nosis have advanced or metastatic disease [4] and even
with chemotherapy have a median survival of one year or
less [5].
Inflammation is recognized both as a condition that leads
to cancer development and also as a condition that arises
due to oncogenic changes in cancer cells [6]. The six hall-
marks of cancer, distinctive and complimentary capabilities
that enable tumor growth and metastatic dissemination are
sustaining proliferative signaling, evading growth suppres-
sors, resisting cell death, enabling replicative immortality,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sis. Inflammation has been described as the underlying or
enabling characteristic that promotes these hallmarks of
cancer [7]. Systemic inflammation besides promoting
tumor growth has also been shown to be responsible for
many cancer related symptoms including cancer cachexia,
anorexia, pain, debilitation and shortened survival [8].
There are various laboratory markers of systemic in-
flammation including plasma C-reactive protein concen-
tration (CRP), hypoalbuminaemia and Glasgow Prognostic
Score (GPS, which combines CRP and albumin), and
absolute white cell and its components (neutrophils, neu-
trophils/lymphocyte ratio (NLR) and platelet/lymphocyte
ratio (PLR) [9]. Of these, NLR have been shown to be a
rapid and a simple parameter of systemic inflammation in
critically ill intensive care unit (ICU) patients with a
NLR > 5 suggesting ongoing systemic inflammation [10].
In patients with completely resected NSCLC, NLR
have not only been shown to be associated with higher
stage but also serve as an independent predictor of sur-
vival [11]. In another study of advanced colorectal can-
cer patients NLR of >5 was shown to be an independent
predictor of overall survivals [9].
We wanted to evaluate if degree of systemic inflamma-
tion at the time of diagnosis in patients with advanced
NSCLC can be a prognostic marker for outcome. For
this purpose we developed a simple index based on pa-
tient’s height, weight, serum albumin and NLR from the
time of diagnosis. We call this advanced lung cancer in-
flammation index (ALI). The purpose of this study was
to see if advanced lung cancer inflammation index (ALI)
at the time of diagnosis can predict survival outcomes in
patients with newly diagnosed metastatic NSCLC.
Methods
All patients diagnosed with stage IV NSCLC at our insti-
tution between Jan 1 2000 and Jun 30 2011 were
screened for this retrospective review. Patients with a
prior history of non-small cell lung cancer presenting
with relapse, prior history of other cancers in preceding
5 years and those with incomplete medical information
or follow up were excluded. Height, weight, absolute
neutrophil count, absolute lymphocyte count and serum
albumin obtained from the medical records were
recorded from the date of diagnosis or from the date
closest to the date of diagnosis. Most data points were
from within 2 weeks of the date of diagnosis and none
were more than 6 weeks after diagnosis.
Radiological response and date of progression were
taken from the medical records as judged at that time by
the treating physician. Date of death was obtained from
tumor registry and or from medical records. Progression
free survival was defined as the time period between date
of diagnosis till radiological progression or deterioration inperformance status rendering patient ineligible for further
treatment or death. Overall survival was defined as the
time period between date of diagnosis and the date of
death or date of last contact if exact date of death is
unavailable. The study was conducted after obtaining
approval from Louisiana state university-Shreveport in-
stitutional review board.
Statistical methods
Clinical indicators were calculated as follows. Student t
test was used to compare means and Pearson Chi-square
test or the Fisher’s exact test was used to compare pro-
portion where appropriate. Kaplan-Meier method was
used to estimate progression free survival and median
overall survival. Log-rank test were used to compare the
survivals among various factors. Multivariate Cox regres-
sion was used to perform survival analysis in order to
estimate the hazards ratio for various factors.
Advanced lung cancer inflammation index (ALI)
The Area under a receiver operating characteristic (ROC)
curve was used to identify the factors that could predict
patient’s response to the treatment or not. Ideally a sur-
vival event should be used in this ROC analysis, however
97.8% of patients are dead and only 4 patients are alive,
therefore responses to treatment or not was used in the
ROC analysis. The areas under ROC curves, c statistics,
were 0.67, 0.61, 0.65, 0.70 and 0.74 for absolute neutrophil
count, absolute lymphocyte count, serum albumin, BMI,
and ALI respectively. Therefore based on the highest value
of area under ROC curve, ALI was used to predict re-
sponses or not to the treatment in the ROC analysis.
The single optimal cut point for ALI score is 18.4 in
which the sensitivity and specificity is 77.3% and 63.9%.
This optimal point was selected by using the minimum
distance between the point 100% sensitive and 100%
specific and any point on the ROC curve. Advance lung
cancer inflammation index (ALI) was defined as follows:
Advance lung cancer inflammation index
ALIð Þ ¼ BMIð Þ  Albð Þ=NLR
Where:
Body mass index BMIð Þ ¼ weight lbð Þ= height inð Þ½ 2  703
Alb = serum albumin in g/dLNeutrophil lymphocyte ratios
(NLR) = ANC/ALCANC: Absolute neutrophil countALC:
Absolute lymphocyte count.
In this study, for simplicity the ALI score were dicho-
tomized as < =18 and >18 in the respectively analysis. All
p-value < 0.05 were considered statistically significant.
The SAS system 9.3 (SAS institute Inc. Gary, NC) was
used to performed all the analyses.
Table 2 NSCLC distribution by histology
N = 173 (%)
Adenocarcinoma 91 (52)
Squamous cell 34 (20)
Poorly differentiated 17 (10)
Adeno-squamous 11 (6)
Non-small cell cancer 6 (3)
Large cell carcinoma 5 (3)
Carcinoma 5 (3)
Bronchoalveolar 2 (1)
Squamous cell-Small cell 1 (0.5)
Mucoepidermoid 1 (0.5)
NSCLC: Non-small cell lung cancer.
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A total of 173 patient records with complete medical
information and follow up were included in the final
analysis. Patient’s characteristics are shown in Table 1.
Median age was 57 years old with (range from 34 to 88 years).
Two thirds of patients were male. African Americans consti-
tuted approximately half of our patient population which is
consistent with demographics in the city.
The most common histology was adenocarcinoma
(52%), followed by squamous cell (20%), poorly differen-
tiated carcinoma (10%) and various other histologies as
shown in Table 2. Epidermal growth factor receptor
(EGFR) mutation status was not available for most (75%)
patients with adenocarcinoma as our cohort included
patients from as early as 2000. Of those patients that
had EGFR mutation information available it was found
to be negative in 65%, positive in 9% and 26% of samples
had insufficient material to test EGFR status (Table 3).Table 1 Patient characteristics with advanced NSCLC
N = 173 (%)

















No chemo 59 (34)
Any chemo 114 (66)
First response assessment
Response to chemotherapy 41 (23)
Stable disease 24 (14)
Progression 39 (23)
Decline in performance status 69 (40)
Survival (months)
Median progression free survival 3.7
Median overall survival 5.1
NSCLC: Non-small cell lung cancer.Different sites of metastatic disease included lung,
liver, brain, bones, adrenal glands, spleen and retroperi-
toneal lymph nodes and each was considered a separate
metastatic site. (54%) of patients had up to 2 metastatic
sites and the rest had more than 2. At the time of diag-
nosis most patients (76%) had an ECOG performance
status of 0–1 and 24% had PS 2 or higher.
About a third (35%) of all patients could not receive any
chemotherapy due to poor PS or co-morbid illnesses. Me-
dian number of chemotherapy cycles was 2 with a range
of 0–24 cycles. At first response assessment 23% had re-
sponse to chemotherapy, 14% had stable disease and 23%
had progression of disease and 40% had decline in PS
making them ineligible for further chemotherapy. Median
progression free survival for the entire group was
3.7 months and overall survival was 5.1 months.
In order to get an estimate of ongoing systemic inflam-
mation at the time of diagnosis we calculated ALI for each
patient using the formula described above. Range of ALI
was 0.46-158.4.Patients were then divided around 50th
percentile mark into two groups, those with ALI of < 18
(more inflammation) and those with ALI of ≥ 18 (less in-
flammation). Their characteristics are listed in Table 4.
There was no significant difference in age at diagnosis, sex
and race and tumor histology between the two groups.
Compared to patients with ALI score of ≥ 18 patients
with an ALI score of < 18 were significantly more likely
to have more than 2 sites of metastatic disease at theTable 3 EGFR mutation status of adenocarcinoma patients
N = 91 (%)
Not available 68 (75)
Tested 23 (25)
EGFR negative 15 (65)
Insufficient material 6 (26)
EGFR positive 2 (9)
EGFR: Epidermal growth factor receptor.
Table 4 Patient characteristics and outcome between those with advanced lung cancer inflammation index ALI score
<18 (more inflammation) and those with ALI score > 18 (less inflammation) at the time of diagnosis
Variable ALI < 18 (n = 83) (%) ALI ≥ 18 (n = 90) (%) P = value
Age (median) 56 58 0.26 (a)
Male 57 (69) 59 (65) 0.74 (b)
AA 42 (51) 48 (53) 0.76 (b)
Adenocarcinoma 51 (61) 53 (59) 0.75 (b)
PS 2-4 27 (32) 15 (17) 0.02 (b)
No chemotherapy 41 (49) 18 (20) <0.001 (b)
>2 metastatic sites 48 (58) 32 (35) 0.003 (b)
Response to chemotherapy 15 (18%) 50 (56%) <0.0001(b)
Median PFS 2.4 5.1 <0.001 (c)
Median OS 3.4 8.3 <0.001 (c)
(a) Student t-test, (b) Chi-square test, (c) Log rant test, AA = African American, PS = Performance status, PFS = Progression free survival, OS = Overall survival.
Significant results shown in bold.
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less likely to receive any chemotherapy (P <0.001) and
very low response to chemotherapy (P < 0.0001). They
also did worse in terms of PFS and OS. Patients with
ALI of <18 had a median PFS of 2.4 months and OS of
3.4 months. Patients with ALI of > 18 had a median PFS
of 5.1 months and OS of 8.3 month. Both PFS and OS
were highly significant between two groups (P < 0.001)
(Figure 1).
In univariate analysis of overall survival age < 60 years
(HR = 1.42, 95% CI 1.03-1.95, P = 0.03), Absolute lympho-
cyte count (ALC) < 1 (HR = 1.82 (1.16-2.87, P = 0.009),
ALI of < 18(HR = 1.97, 95% CI 1.45-2.6, <0.0001) and
no chemotherapy (HR =2.36, 95% CI 1.7-3.2, <0.0001)
were associated with significantly worse outcome. Simi-
larly PS of 0–1 (HR = 0.64, 95% CI 0.44-0.93, P = 0.01)
and 1–2 metastatic sites (HR = 0.54, 95% CI 0.39-0.73,
P = 0.0001) were associated with better outcome
(Table 5).
On multi-variate cox regression analysis adjusted for
sex, race, PS and histology ALI is a significant predictor
of both PFS and OS. ALI score of < 18 has a hazard ratio
of 1.66 (1.18-2.33, P = 0.003) for PFS and 1.42 (95% CI
1.003-2.01, P =0.047) for OS. With an ALI < 18 at the
time of diagnosis, the risk of dying increases by 42% as
compared to ALI ≥ 18 (Table 6).
Discussion
Cancer and inflammation are closely linked and many
inflammatory conditions increase the risk of cancer de-
velopment like inflammatory bowel disease and in-
creased risk of colorectal cancer, hemochromatosis and
liver cancer [12] and sjogren’s syndrome and lymphoma
[13]. Similarly in a nested case control study of 592 lung
cancer patients and 670 controls pre-diagnostic elevated
C-reactive protein was found to be associated with in-
creased risk of lung cancer development (odds ratio[OR], 1.98; 95% CI, 1.35 to 2.89; P-trend < .001 for fourth
quartile [Q4, ≥5.6 mg/L] v Q1 [< 1.0 mg/L]) [14].
Systemic inflammation is also linked to poor outcome in
cancer patients. In 102 unresctable pancreatic cancer pa-
tients elevated C-reactive protein at the time of diagnosis
was found to be an independent poor prognostic factor.
Median survival of those with an acute phase protein re-
sponse (CRP > 10 mg/L, n = 45) was 66 days compared
with 222 days for those with no acute phase protein re-
sponse (n = 57, P = 0.001, Mann–Whitney U test) [15].
In patients with inoperable stage III and IV NSCLC,
an inflammatory score called Glasgow prognostic score
(based on serum CRP and albumin) was shown to be of
prognostic value in predicting outcome (HR 1.70,95% CI
1.23-2.35, P = 0.001) [16]. In an another study of mostly
stage III and few stage IV NSCLC patients elevated CRP
at the time of diagnosis was associated with increased
weight loss (P = 0.004), reduced albumin (P = 0.001), re-
duced performance status (p = 0.06), increased fatigue
(P = 0.01) and reduced survival (HR 1.93,95% CI 1.41-2.6,
P <0.001) [17].
Most patients with lung cancer at the time of diagnosis
have metastatic disease. ALI was developed to assess on-
going systemic inflammation in these patients. Both
weight loss and a low serum albumin are associated with
ongoing systemic inflammation [17]. NLR, a marker of
systemic inflammation has been found to predict poor
outcome in patients with different cancers including lung
cancer [11]. ALI was developed using these markers into
an easy to calculate unified index called advanced lung
cancer inflammation index. Moreover as opposed to
Glasgow prognostic score it is exclusively derived from pa-
tients with stage IV or metastatic lung cancer [16].
There was no difference in ALI score based on tumor
histology suggesting that both adenocarcinoma and non-
adenocarcinoma generate similar degree of systemic in-
flammation. In our study patients with ALI score of < 18
Figure 1 Kaplan-Meir survival curve for (PFS) progression free survival and (OS) overall survival between patients with advanced lung
cancer inflammation index of (< 18, high inflammation) and (>18, low inflammation). (Time in months).
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have more sites of metastatic disease, have a poor per-
formance status , receive no chemotherapy and had an
overall poor PFS (2.4 vs 5.1 months, P < 0.001) and OS
(3.4 vs 8.3 months < 0.001). This data suggests progres-
sion of cancer through the body leads to higher level of
systemic inflammation resulting in poor performancestatus, less chance of getting chemotherapy and ulti-
mately earlier demise.
In our cohort a third of all patients never received any
chemotherapy including 50% of patients with ALI <18.
Many such patients have poor performance status at the
time of diagnosis hence excluding them from standard
treatment as well as participation in clinical trials. As
Table 5 Univariate analysis of clinical characteristics on progression free and overall survival in patients with
metastatic non-small cell lung cancer
Variable PFS: HR, (95% CI) P = value OS: HR, (95% CI) P = value (a)
Age < 60 1.31 (0.96-1.79) 0.08 1.42 (1.03-1.95) 0.03
Gender (Female/Male) 1.14 (0.82-1.58) 0.41 0.97 (0.7-1.35) 0.88
Race (AA/White) 0.89 (0.65-1.20) 0.44 1.08 (0.8-1.47) 0.59
Histology (Adeno/Other) 1.03 (0.76-1.4) 0.82 1.01 (0.74-1.38) 0.90
PS (0-1/ 2–4) 0.62 (0.43-0.89) 0.009 0.64 (0.44-0.93) 0.01
Mets (1-2/ >2) 0.47 ( 0.34-0.64) <0.0001 0.54 (0.39-0.73) 0.0001
No chemotherapy 2.25 (1.62-3.13) <0.0001 2.36 (1.7-3.2) <0.0001
ALC <1 1.61 (1.02-2.53) 0.03 1.82 (1.16-2.87) 0.009
NLR < 5 0.58 (0.42-0.8) 0.001 0.57 (0.41-0.79) 0.0008
ALI < 18 2.26 (1.65-3.09) <0.0001 1.97 (1.45-2.68) <0.0001
a) Cox-proportional hazard regression model.
Abbreviations: AA African Americans, Adeno Adenoacrinoma, ALC Absolute lymphocyte count, ALI Advanced lung cancer inflammation index, PS performance
status, Mets metastatic sites, NLR Neutrophil/lymphocyte ratio. Significant results shown in bold.
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of systemic inflammation and it may be the reason for
their poor PS and less change of receiving any chemo-
therapy. In light of this data gauging systemic inflamma-
tion in patients with advanced NSCLC at the time of
diagnosis could be an important clinical consideration.
In multi-variate analysis age < 60 years, more than two
metastatic sites, no chemotherapy and ALI < 18 were in-
dependently associated with worse outcome. Of these
age and number of metastatic sites are non-modifiable
variables. High systemic inflammation as represented by
ALI <18 hence represents a potential therapeutic area
for improving patient outcome.
In our cohort patients with age < 60 years had worse
outcome. The reason for this is unclear to us. They were
also more likely to have > 2 sites of metastatic disease
(54% vs 32%, P = 0.004). There was no difference in ALI
score between those with age < 60 or more than 60. One
explanation could be that in this cohort, those who got
diagnosed with cancer at a young age may have a more
biologically aggressive disease, hence more metastatic
sites and worse outcome.
If systemic inflammation is a poor prognostic marker as
suggested by GPS and our study, then combining anti-
inflammatory agents with chemotherapy makes sense. In
a randomized placebo controlled phase III study ofTable 6 Multi-variate analysis of clinical characteristics on pro
metastatic non-small cell lung cancer
Variable PFS: HR (95% CI) P =
Age <60 years 1.46 (1.03-2.07) 0.0
No chemotherapy 2.04 (1.38-3.01) 0.0
Mets 1-2 0.56 (0.39-0.79) 0.0
ALI <18 1.66 (1.18-2.33) 0.0
a) Cox proportional hazard regression model, Variables adjusted included sex, race,
ALI advanced lung cancer inflammation index, Mets metastatic sites. Significant resuadvanced NSCLC patients platinum doublet chemother-
apy was combined with celecoxib 400 mg twice daily or
placebo. However there was no difference in median pro-
gression free survival (HR 0.8, 95% CI, 0.6-1.1; P = 0.25) or
median overall survival (HR 0.9; 95% CI, 0.6-1.2; P = 0.32)
between the two groups. Moreover cyclooxygenase-2
(COX-2) expression was neither a prognostic nor a pre-
dictive marker of use of celecoxib [18]. In this study most
patients had PS of 0–1 suggesting low systemic inflamma-
tion. Perhaps combining anti-inflammatory agents with
chemotherapy will be more beneficial in patients with high
level of systemic inflammation.
There are several drawbacks of using ALI. This data is
based on retrospective chart review hence many data
points may not be accurately recorded. Patients height,
weight, albumin, ANC and ALC were not necessarily
from the same date though most were within two weeks
of diagnosis. Also ALI is a continuous variable hence
there may be little difference between ALI of 17 and 19
though they fall on the side of high risk and low risk re-
spectively based on current study.
This study sheds light on the importance of assessing
or gauging systemic inflammation in advanced NSCLC
patients as a prognostic marker. However ALI should be
validated in a prospective cohort study. In such study
ALI should be compared with tumor specific mutationsgression free and overall survival in patients with
value OS : (95% CI) P = value (a)
3 1.64 (1.14-2.36) 0.006
003 2.12 (1.42-3.18) 0.0002
01 0.69 (0.49-0.97) 0.03
03 1.42 (1.003-2.01) 0.047
Performance status, histology.
lts shown in bold.
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tions are associated with higher systemic inflammation.
As far as treatment is concerned patients with higher
systemic inflammation at the time of diagnosis should
be considered high risk and should be started on sys-
temic chemotherapy without delay perhaps initially with
single agent only, provided their overall performance
status and organ function allows such treatment to be
given. Further studies should be conducted combining
anti-inflammatory agents with chemotherapy in patients
with high degree of systemic inflammation to see if this
combination is beneficial.
Conclusion
Advanced lung cancer patients should have an assess-
ment of degree of systemic inflammation at the time of
initial clinical evaluation. Advanced lung cancer inflam-
mation index (ALI) is an easy to calculate tool to assess
ongoing systemic inflammation in these patients. High
systemic inflammation as judged by ALI of < 18 is an in-
dependent prognostic marker of poor outcome. It also
correlates with widespread metastatic disease, poor per-
formance status and less chance of receiving any chemo-
therapy. However, it should be validated in a prospective
cohort study.
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